Enlivex Ltd. (Nasdaq: ENLV) reported $1.23 billion in net income and $25.48 EPS for 2025, driven by significant appreciation in its $2.31 billion treasury and derivative asset portfolio. Backed by a differentiated dual strategy—combining clinical-stage longevity therapeutics with exposure to decentralized prediction markets infrastructure—the company is positioning for sustained value creation at the intersection of biotech and digital asset innovation.

Off The Hook YS Inc. (NYSE American: OTH) launched NextBoat AI—an industry-first platform leveraging proprietary transaction data and AI to match buyers with ideal vessels faster and more precisely—at the Palm Beach International Boat Show. Built on thousands of transactions and designed to unlock marketplace liquidity, the platform positions the company to streamline discovery and accelerate sales cycles across the expansive $57 billion U.S. marine market.

TMC the metals company (NASDAQ: TMC) reported year-end 2025 liquidity of approximately $162 million while advancing key milestones toward commercial deep-sea mining, including a significantly expanded 65,000 km² resource area and regulatory progress with NOAA . The company is accelerating its path to production through strategic partnerships, a proposed large-scale U.S. processing hub in Texas, and positioning within critical minerals supply chains essential to energy, defense, and infrastructure markets.

Calidi Biotherapeutics (NYSE American: CLDI) has partnered with Avance Clinical to accelerate Australian regulatory approval and initiate first-in-human trials of CLD-401, its novel tumor-targeting oncolytic virotherapy. Leveraging its RedTail platform, the company is advancing a differentiated genetic medicine designed to selectively replicate in tumors and activate immune response, targeting large unmet needs across solid tumor indications.